See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Virtus LifeSci Biotech Clinical Trials ETF (BBC) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Virtus LifeSci Biotech Clinical Trials ETF (BBC) - free report >>
Image: Bigstock
Biotech ETF (BBC) Hits New 52-Week High
For investors seeking momentum, Virtus LifeSci Biotech Clinical Trials ETF (BBC - Free Report) is probably on radar now. The fund just hit a 52-week high and is up nearly 76% from its 52-week low price of $18.49/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
BBC in Focus
This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trial stage. It has a well-diversified portfolio of 74 stocks with key holdings in the hottest stock Juno Therapeutics currently in the market. BBC charges 79 bps in fees per year from its investors (see: all the Healthcare ETFs here).
Why the Move?
The biotech segment of the broad equity market has been an area to watch lately given that the new tax legislation has enticed companies in this corner to bring offshore cash back home, leading to a wave of mergers and acquisitions. Additionally, the slower growth in mature drugs has compelled prominent biotechs to acquire smaller ones with promising pipelines. The latest catalyst is JUNO, which has agreed to be acquired by Celgene Corporation for $87 per share in cash, or $9 billion.
More Gains Ahead?
Currently, BBC has a Zacks ETF Rank #2 (Buy) with a High risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank, so there is definitely still some promise for those who want to ride on this surging ETF a little longer.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>